FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024.
Aarti Drugs Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Nucleus Software Buyback 2024 is a Tender Offer proposed to list at BSE, NSE.
Aarti Drugs Ltd. | Nucleus Software Exports Ltd. | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Logo | ||||||||||||||||||||
Type of Buyback | Tender Offer | Tender Offer | ||||||||||||||||||
Listing At | BSE, NSE | BSE, NSE | ||||||||||||||||||
Face Value | ₹10 per share | ₹10 per share | ||||||||||||||||||
Buyback Price | ₹900 per share | ₹1615 per share | ||||||||||||||||||
Issue Size | 6,65,000 shares | 4,48,018 shares | ||||||||||||||||||
Issue Size (Amount) | ₹59.85 Crores | ₹72.35 Crores | ||||||||||||||||||
Buyback Ratio |
|
|
||||||||||||||||||
Registrar | Link Intime India Private Ltd | Kfin Technologies Limited | ||||||||||||||||||
Lead Managers | Inga Ventures Pvt Ltd | Corporate Professionals Capital Private Ltd | ||||||||||||||||||
Necessity of the buyback | The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company’s management strives to increase equity shareholder's value and the Buyback would result in amongst other things:
|
The current Buyback is a capital allocation decision taken to seek a fairer valuation of the Company's stock while improving the Company's Return on Equity and increasing shareholder value in the longer term. The Buyback is being undertaken by the Company after taking into account the strategic and operational cash needs of the Company in the medium term and thereby returning surplus funds to the equity shareholders, which are over and above its ordinary capital requirements and over any current investment plans, in an expedient, effective and cost-efficient manner. The Buyback is being undertaken for the following reasons:
|
Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aarti Drugs Buyback 2024 Buyback record date is Sep 05, 2024. Nucleus Software Buyback 2024 Buyback record date is Sep 03, 2024.
Aarti Drugs Ltd. | Nucleus Software Exports Ltd. | |
---|---|---|
Record Date | Sep 05, 2024 | Sep 03, 2024 |
Offer Open Date | Sep 11, 2024 | Sep 09, 2024 |
Offer Closure Date | Sep 19, 2024 | Sep 13, 2024 |
Last date for receipt of tender forms | Sep 19, 2024 | Sep 13, 2024 |
Finalisation of buyback | Sep 25, 2024 | Sep 20, 2024 |
Last Date for settlment of bids | Sep 26, 2024 | Sep 23, 2024 |
Last Date for extinguishment of shares | Oct 08, 2024 | Oct 03, 2024 |
Comparison of Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.
Aarti Drugs Ltd. | Nucleus Software Exports Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Aarti Drugs Ltd. Financial Information (Restated Consolidated)Aarti Drugs Ltd.'s revenue decreased by -7% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Nucleus Software Exports Ltd. Financial Information (Restated Consolidated)Nucleus Software Exports Ltd.'s revenue increased by 31% and profit after tax (PAT) rose by 50% between the financial year ending with March 31, 2024 and March 31, 2023.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price at BSE | Stock price at BSE (in preceding 3 months)
|
Stock price at BSE (in preceding 3 months)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price at NSE | Stock price at NSE (in preceding 3 months)
|
Stock price at NSE (in preceding 3 months)
|
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|